StemCell Therapy

The American health-care industrys pivot to personalized medicine has attracted the interest of an unlikely group of companies government contractors.

As health-care providers explore this new model of treatment, which involves the study of the human genome to provide personalized care, they face a problem with which many in government are familiar: analyzing an overwhelming amount of data.

Were literally drowning in data, said Norman Sharpless, an oncologist and director of the University of North Carolinas Lineberger Comprehensive Cancer Center.

The amount of information generated from sequencing human genes is growing at a rapid clip, and it has triggered a rush of clinical trials aimed at linking that knowledge to medical treatment. Cataloguing all this new information requires computational power and sophisticated analysis, Sharpless said.

For IT contractors, many of which are based in the Washington region, the flood of information presents a simple business opportunity: The same skills used to crunch massive amounts of data for cyberthreats or warfare intelligence can be applied to personalized medicine.

The governments growing interest in this field also is a factor.

In his State of the Union speech this year, President Obama outlined an initiative to explore the uses of precision medicine. His budget includes a request for $215million to fund research in this area. The White House also hired its first chief data scientist, DJ Patil, who has made precision medicine one of his priorities.

Many contractors, especially those in information technology, have been eager to pursue opportunities in precision medicine as they look to add lines of business to make up for cuts in other parts of the federal budget as overall spending slows.

That is why so many different kinds of businesses including defense giants Lockheed Martin and Northrop Grumman, and cloud storage providers such as Amazon Web Services and Google are getting in on the game.

Lockheed Martin announced a partnership this year with Illumina, a San Diego company that provides relatively inexpensive genome sequencing technology, to study the DNA of populations and develop personalized health-care solutions. For Illumina, the partnership offered access to Lockheeds experience in managing large-scale information systems, Alex Dickinson, Illuminas senior vice president of strategic initiatives, said at the time.

Go here to see the original:
Personalized medicine could mean big business for D.C ...

What makes cancer cells different, and dangerous? Among the myriad genetic alterations observed in tumors, only some propel cancer cells to proliferate abnormally, survive inappropriately and resist the drugs administered to destroy them. Furthermore, every cancer is different, as multiple pathways can lead to the same lethal conclusion. To know which alterations represent important therapeutic targets, we need to understand their place in the vast molecular network that underpins cellular function. We are using multiple genomic, proteomic, computational, and in vivo approaches to build a comprehensive wiring diagram for cancer cells and their molecular environment. This blueprint will lead us to better, more sophisticated strategies to control individual cancers and combat drug resistance.

Featured Faculty: Matthew Vander Heiden

Learn more about the Vander Heiden lab and their efforts to better understand cancer cell metabolism and how small molecules might be used to activate enzymes and restore the normal state of cells.

Participating Intramural Faculty

To browse recent publications by these and other Koch Institute faculty members, visitProgress, our monthly research review.

Read more from the original source:
The Koch Institute: Personalized Medicine - David ...

Call for Papers

If you would like to be considered for an oral presentation at this meeting, Submit an abstract for review now!

Oral Presentation Submission Deadline: 16 June 2015

You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

Poster Submission Deadline: 23 September 2015

Exhibition Team, exhibitors@selectbio.com +44(0)1787 315110

Samir Hanash, Director, Red & Charline McCombs Institute for the Early Detection & Treatment of Cancer, MD Anderson Cancer Center Sherry Yang, Chief, National Clinical Target Validation Laboratory, National Cancer Institute Jeremy Segal, Director of Bioinformatics, Division of Genomic and Molecular Pathology, University of Chicago Valerie Taly, Group Leader/Researcher, Universite Paris Descartes Reinhard Bttner, Director, Cologne University Hospital Catherine Alix-Panabieres, Associate Professor, University Medical Center of Montpellier Julia Stingl, Professor/Director of the Division of Research, BfArM Federal Institute for Drugs and Medical Devices Edith Schallmeiner, Global Team Director - NPT, Novartis Arijit Chakravarty, Director, Takeda Pharmaceuticals Co Ltd Ryan Richardson, Healthcare Investment Banking Associate, J.P. Morgan Leeza Osipenko, Associate Director, National Institute for Health and Care Excellence

Excerpt from:
Personalized Medicine and its Impact in the Clinic

Given the nature of personalized medicine, the FDA places high priority on helping to ensure that the agency, drug manufacturers, physicians and patients have adequate information about the product and its use. Product labeling and tracking of use in the marketplace are critical to the proper application of personalized medication tools.

Product Labeling

The FDA requires product labeling to be balanced, scientifically accurate and not misleading, and that clear instructions be communicated to healthcare practitioners for drug prescribing and/or administration. Personalized medicines that may only be safe and effective in particular sub-populations, or must be administered in different doses in different sub-populations, must be labeled accordingly. To date, the labeling of more than 100 approved drugs contain information on genomic biomarkers (including gene variants, functional deficiencies, expression changes, chromosomal abnormalities, and others).

Post-market Surveillance

While personalized medicine will likely allow for more focused clinical trials by increasing the proportion of responders in the trial or increasing the average effect size, or both, one implication of dramatically smaller pre-market exposure is a general increase in the importance of and emphasis on post-market monitoring, because relatively rare adverse events, in particular, are unlikely to show up when a drug is being tested in a small population, may arise when a broader population is treated. Post-market surveillance, then, is critical to the success of personalized medicine.

For more information:

Read more here:
Personalized Medicine - Food and Drug Administration

Personalized Medicine: The Background

Personalized medicine is an extension of traditional approaches to understanding and treating illness. Since the beginning of the study of medicine, physicians have employed evidence found through observation to make a diagnosis or to prescribe treatment. In the past, this was presumably tailored to each individual, but personalized medicine makes treatment more specific.

In the modern conception of personalized medicine, the tools provided to the physician are more precise, probing not just the obvious, such as a tumor on a mammogram or cells under a microscope, but the very molecular makeup of each patient. Looking at the patient on this level helps the physician get a profile of the patients genetic distinction, or mapping. By investigating this genetic mapping, medical professionals are then able to profile patients, and use the found information to plan out a course of treatment that is much more in step with the way their body works. Genomic medicine and personalized medicine use genetic information to prevent or treat disease in adults or their children.

Having a genetic map or a profile of a patients genetic variation can then guide the selection of drugs or treatment processes. This can be used to minimize side effects or to create a strategy for a more successful outcome from the medical treatment. Helping the physician cover all the bases is imperative. Genetic mapping can also indicate the propensity to contract certain diseases before the patient actually shows recognizable symptoms, allowing the physician and patient to put together a plan for observation and prevention.

The ability to profile how genes are put together in sequence and expression level is helping to redefine the ways in which medical professionals classify diseases and discover treatments, allowing physicians to go beyond the "one size fits all" model that may be ineffective or have undesirable side effects. Through further organization, and the use of personalized medicine, medical professionals are developing many sub populations for complex diseases and physical conditions such as these.

Personalized medicine may be able to help the medical community make the most effective clinical decisions for each patient on an individual level.

Personalized medicine, when coupled with personal pharmacogenetics, is a unique approach that may be well suited for the health challenges we face in the new millennium. Although the medical and scientific communities, through research and discovery, got the upper hand over many of the diseases weve encountered since the advent of advanced medicine, we are still threatened by many more complicated diseases.

Diseases like Diabetes, heart disease, cancer and Alzheimers are thought to caused by a combination of genetic and other factors. Coupled with the fact that they tend to be chronic, they place a significant burden on not only the patient, but on the healthcare system as a whole. Personalized medicine aims to provide the tools and knowledge to fight chronic diseases and treat them more effectively than ever before.

Genetic profiles can help physicians to better discern subgroups of patients with various forms of cancer in addition to other complex diseases, helping to guide doctors with accurate forms of predictive medicine and preventative medicine. With personalized medicine, the physician is intending to select the best treatment protocol or even, in many cases, avoid passing the expense and risks of unnecessary medical treatments on to the patient altogether. Also, personalized medicine, when used correctly, aims to guide tests that detect variation in the way individual patients metabolize various pharmaceuticals. Personalized medicine is working to help determine the right dose for a patient, helping to avoid hazards based on familial history, environmental influences, and genetic variation.

See the original post here:
Personalized Medicine - Information and Resources

Personalized medicine and pharmacogenomics Pharmacogenomics holds the promise that drugs might one day be tailored to your genetic makeup. By Mayo Clinic Staff

Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.

Your age, lifestyle and health all influence your response to medications. But so do your genes. Scientists are working to match specific gene variations with responses to particular medications.

With that information, doctors can tailor treatments to individuals. That's what pharmacogenomics is all about. Part of a new field called personalized medicine, pharmacogenomics offers the promise of predicting whether a medication is likely to help or hurt you before you ever take it.

Imagine you've had a heart attack and your doctor wants to give you medication to lower your risk of having another. Taking into account such factors as your weight, age and medical history, your doctor might prescribe a blood-thinning drug to help prevent blood clots from causing another heart attack.

Without testing, neither you nor your doctor knows exactly how you'll react to the medication. It may not work for you, or you may have serious side effects such as bleeding. You might have to try different doses or even different medications before finding a treatment that works for you.

Pharmacogenomics speeds up that process. Before you take a single dose of medication, you can have a test to see how you're likely to respond to the medication. With that information, your doctor can tailor the dose or avoid that drug entirely and prescribe a different one.

.

Continue reading here:
Personalized medicine and pharmacogenomics - Mayo Clinic

This site uses cookies to improve performance. If your browser does not accept cookies, you cannot view this site.

There are many reasons why a cookie could not be set correctly. Below are the most common reasons:

This site uses cookies to improve performance by remembering that you are logged in when you go from page to page. To provide access without cookies would require the site to create a new session for every page you visit, which slows the system down to an unacceptable level.

This site stores nothing other than an automatically generated session ID in the cookie; no other information is captured.

In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a website to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it.

More here:
Personalized Medicine

Policy Updates "Precision Medicine" Proposal Includes $215M for NIH, FDA, ONC

President Obamas Precision Medicine Initiative, which he unveiled on Jan. 30, will account for $215 million in his budget proposal. The funds will be divided between the National Institutes of Health (NIH), FDA and the Office of the National Coordinator for Health Information Technology (ONC), with the majority of the money being used for the development of a voluntary national research cohort. Read PMC's press release on the initiative Watch Obama's announcement of the initiative View the White House fact sheet

21st Century Cures Draft Tackles Device Review Pathways, Biomarkers Among other topics, the U.S. House Energy & Commerce Committee's recently released "21st Century Cures" draft bill tackles innovative device review pathways and biomarker qualification. Access a summary of the bill

Senate HELP Committee White Paper Explores FDA, NIH Processes The U.S. Senate Health, Education, Labor & Pensions (HELP) Committee's recent white paper explores how well FDA and the National Institutes of Health (NIH) processes support innovation. Download the white paper

In its response letter to FDA on the agency's proposed framework for regulating laboratory-developed tests (LDTs), PMC suggests that the agency publish draft guidance documents on risk classification and Clinical Laboratory Improvement Amendments (CLIA) harmonization alongside a second draft of the original framework documents. Download the Letter

PMC Joins Stakeholders for "Precision Medicine" Announcement PMC's Amy Miller joined stakeholders at the White House on Jan. 30 when Obama announced his "Precision Medicine Initiative." Watch the announcement

PMC Engages 21st Century Cures PMC advocates for additional draft guidance documents from FDA in this 21st Century Cures response letter. Download the letter

PMC Analysis: 20 Percent of 2014 Approvals Personalized Medicines A PMC analysis of FDA's 2014 novel new drug approvals shows that more than 20 percent were personalized medicines. Download the analysis

PMC Summarizes 2014 In this blog post, PMC's Amy Miller reflects on 2014, which she calls "the year of the patient." Read the post

See the rest here:
Personalized Medicine Coalition precision medicine

California sees opportunities in personalized medicine. Earlier this month, Governor Brown announced the creation of a two year initiative California Initiative to Advance Precision Medicine to begin building infrastructure and assembling resources necessary to advance precision medicine-orientated data, tools and applications. See California Launches Initiative to Advance Precision Medicine. Continue reading this entry

President Obamas precision medicine initiative earmarked over $200 million from his proposed 2016 budget to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier.[1] The National Institutes of Health (NIH) and the National Cancer Institute (NCI) will be the major benefactors if the proposed budget for this initiative is approved. A recent article co-authored by Drs. Francis S. Collins and Harold Varmus, directors of the NIH and NCI, respectively, identifies precision medicines critical needs and discusses how the Presidents initiative will help accelerate progress toward a new era of precision medicine.[2] Continue reading this entry

23andMe is not a traditional diagnostics company. Rather than seeking to directly sell its services to health care professionals, 23andMe went straight to the consumer, offering genetic screening and analysis in a mail-order fashion. For ninety-nine dollars, customers only needed to send in a saliva sample and the company would analyze the customers genetic information, interpret and report the results directly to the consumer, bypassing the physician or genetic counselor. Continue reading this entry

Late last year, the USPTO issued its modified and revised 2014 Interim Guidance on Patent Subject Matter Eligibility (Interim Guidance) to assist patent examiners and the public in determining if a claim presented for examination is patent-eligible in view of recent U.S. Supreme Court decisions, namely Alice Corp., Myriad, and Mayo. In addition to streamlining the analysis of patent claims directed to any one of the judicial exceptions to patent-eligibility (abstract ideas, laws of nature and physical phenomena), the USPTO provided illustrative examples to be used in combination with the Interim Guidance. One such example discussed the patent-eligibility of claims directed to stem cells or regenerative medicine. Fortunatelyfor these industries, application of the Interim Guidance as discussed in the example finds that many stem cell technologies are patent-eligible. Continue reading this entry

Personalized medicine has a friend in high places. President Obama recently announced an initiative to support precision or personalized medicine. In very general terms, the President stated during his 2015 State of the Union address that he wanted the United States to lead a new era of medicine an era that delivers the right treatment at the right time. Continue reading this entry

Read the original post:
Personalized Medicine Bulletin Personalized Medicine ...

Articles

Personalized medicine has a vision to avoid a costly and prolonged trial and error approach that can leave the patient anguishing unnecessarily from side effects, while simultaneously losing precious time in the fight against the disease. As evidence of the benefits of personalized medicine continue to grow, a network of laws, policy, education, and clinical information is building around personalized medicine to support its use in the medical community.

Personalized medicine introduces new treatment protocols, which create the ability to use molecular tracking elements that signal the risk of disease on a genetic level. This alerts the medical community to its presence before clinical indications and symptoms appear. This healthcare strategy is focused on preventive medicine and intervention, rather than a reaction to highly developed stages of disease. Such a strategy intends to delay disease onset and help the patient avoid mounting healthcare costs.

The cost of healthcare in the United States is on an upward climb, which is highly unsustainable. Proponents of personalized medicine believe that by following the practice of personalized medicine and working it into the existing healthcare system, we as a nation can resolve many of the inefficiencies inherit therein. These inefficiencies, such as a dosing system based on trial and error, severe reactions to a drugs, reactive treatment, and poorly timed diagnoses are contributing to mounting healthcare costs.

There are specific examples that the pharmacogenic system of personalized medicine is generating tangible results. Authors of various studies exploring potential healthcare cost savings from using genetic testing estimated that the use of a genetic test to properly dose various pharmaceuticals could reduce overall healthcare costs.

The substantiation of the benefits of personalized medicine is accumulating rapidly, and the real world applications of this knowledge are beginning to take root as well. Three areas of technology are key to making personalized medicine a presence in our healthcare system. New tools to decode the human genome, large-scale studies that help link genetic variation to disease, and a healthcare information technology system that supports the integration of clinical data in addition to the research is spawned from, as well as the ability of physicians to track every aspect of patient care according to genetic and molecular profiles to facilitate tailoring of treatment.

In addition, technological advancements have enabled personalized medicine to be brought to the public through the use of personal genetic testing. The systems for sequencing DNA or checking for genetic variation are essential to progress in both research and doctor to patient applications. DNA microscopes borrow technology from circuit manufacturing, helping scientists detect hundreds of thousands of genetic variations on a single chip. They are instrumental in identifying which variations are associated with any given disease.

In the last five years, the number of changes in single DNA chemical building blocks of the genome, which can be examined in a 1 cm chip increased from 250,000 to 920,000. It is estimated that there are millions such variations in the human genome. There are many subfields that are being employed as possible tools in the study of personalized medicine. Genomics and Transcriptomics offer information on genetic variation as well as the level of gene expression. Metabolomics examines the small molecules that are the byproducts of chemical reactions within the human body. Proteomics examines the entire formation of proteins made by cells. These tools are very important because what was once thought to be a single disease characterized by a common set of physical signs, for instance, asthma or breast cancer and symptoms may be several distinct conditions, or it may be a single disease with a variety of handling options.

Those in favor of personalized medicine see a future in which each person, on the day of their birth, is provided with his full genomic sequence to place into a personal medical record. That information from a personal genome would then be used to allow physicians to develop a more proactive healthcare approach based on the patients susceptibility to different diseases. The reactions to pharmaceuticals and reactions to different types of medicine would be assisted with that information as well. Advances in genomic sequencing are clearly on an exponential curve, and many scientists believe that with the help of venture capital we will see a dollar amount applied on a genome in the coming years.

Within the past few years, a growing number of businesses have begun to offer direct to consumer genetic tests. These tests are designed to help individuals better understand their genetic predisposition for a given health condition. As supporting technology has become less exclusive, genomics companies have started on the track to offer consumers whole genome scanning and associated information on individual genetic predisposition for a wide-ranging list of conditions concurrently.

Read more:
Personalized Medicine - Articles

STEM CELLS Groundbreaking Discovery. The FUTURE of Personalized Medicine ?
STEM CELLS Groundbreaking Discovery. The FUTURE of Personalized Medicine ? Stem cell researchers are heralding a "major scientific discovery", with the potential to start a new age of personalise...

By: Beadledom911

Read more:
STEM CELLS Groundbreaking Discovery. The FUTURE of Personalized Medicine ? - Video

Spotlight on Genomics: Understanding Our Genes - A Step to Personalized Medicine
Visit: http://www.uctv.tv/) Learn about the essential role of genomics in the development of stem cell based therapies. Craig Venter, president and founder ...

By: UCtelevision

See the article here:
Spotlight on Genomics: Understanding Our Genes - A Step to Personalized Medicine - Video

Pastor Chui Adult Stem Cell Breakthroughs Continue
This is a 9-minute sermon from science. It outlines the accomplishments of adult stem cells in several areas of applications, including heart repair, automatic wound repair, personalized medicine, rebuilding skeletal muscle, stem cell-specific expressions, and new kinds of stem cells to establish fountain of youth. Adult stem cells have high expectations of success and free from ethical concerns. That is why the Japanese medical doctor Shinya Yamanaka won the Nobel Prize in 2012.From:Christopher ChuiViews:1 0ratingsTime:09:21More inEducation

Read the original here:
Pastor Chui Adult Stem Cell Breakthroughs Continue - Video

Nina Tandon: Could tissue engineering mean personalized medicine?
Each of our bodies is utterly unique, which is a lovely thought until it comes to treating an illness -- when every body reacts differently, often unpredictably, to standard treatment. Tissue engineer Nina Tandon talks about a possible solution: Using pluripotent stem cells to make personalized models of organs on which to test new drugs and treatments, and storing them on computer chips. (Call it extremely personalized medicine.) TEDTalks is a daily video podcast of the best talks and performances from the TED Conference, where the world #39;s leading thinkers and doers give the talk of their lives in 18 minutes (or less). Look for talks on Technology, Entertainment and Design -- plus science, business, global issues, the arts and much more. Find closed captions and translated subtitles in many languages at http://www.ted.com Follow TED news on Twitter: http://www.twitter.com Like TED on Facebook: http://www.facebook.com Subscribe to our channel: http://www.youtube.comFrom:TEDtalksDirectorViews:8662 521ratingsTime:06:20More inScience Technology

Read the original:
Nina Tandon: Could tissue engineering mean personalized medicine? - Video

CAMBRIDGE, Mass., BOSTON and NEW YORK, Nov. 8, 2012 /PRNewswire/ --GNS Healthcare, Inc. (GNS), the leading healthcare data analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Dana-Farber Cancer Institute (Dana-Farber) and Mount Sinai School of Medicine (Mount Sinai) to create a data-driven computer model of multiple myeloma, the second most common blood cancer in the U.S. that constitutes approximately one percent of all cancers. Created using GNS's supercomputer-driven REFS (Reverse Engineering and Forward Simulation) platform, the models will be used to help researchers discover novel therapies for the disease and to help determine the best existing treatments for patients.

"We have made encouraging progress at Dana-Farber Cancer Institute in using gene profiling, proteomic and signaling studies in tumor cell samples treated with existing and novel medicines to get a better understanding of myeloma pathogenesis and to develop novel targeted therapies," said Dr. Ken Anderson, Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber and Kraft Family Professor of Medicine at Dana-Farber and Harvard Medical School.

"Because of this progress, our team is excited about deploying a powerful, supercomputer driven approach using our multi-layered genomic data to develop computer models to directly define the integrated underlying circuitry of myeloma. We look forward to using these models to identify, create, and implement better treatments for individual multiple myeloma patients," said Dr. Nikhil Munshi, Associate Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber and Associate Professor of Medicine, Harvard Medical School.

"GNS will apply its Big Data analytics platform to create a disease-specific computer model that will yield a powerful new resource to the multiple myeloma research and clinical communitywith the ultimate aim of better outcomes for patients," said GNS CEO and co-founder Colin Hill. "This collaboration with Dana-Farber and Mount Sinai will create models that will help transform the tremendous amount of data coming from new technologies, such as next-generation sequencing, into predictive computer models of disease progression and treatment response for scientists and clinicians. This project is one of many examples of our work in challenging, complex and, sometimes rare, diseases."

In this collaboration, GNS will employ the REFSplatform to reverse engineer network models from next-generation genetic sequencing, proteomic, outcomes and other clinical data. Results from millions ofin silico simulations of the REFS models will provide new insights into the fundamental mechanisms of multiple myeloma, enabling the identification of novel intervention points in the disease for specific groups of patients and the development of more effective medicines.

"Prior published work has shown us that approaches like the REFS platform can develop integrated network models of disease that can be used to uncover novel drivers of disease," said Dr. Eric Schadt, Director of the Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences and the Jean C. and James W. Crystal Professor of Genomics at Mount Sinai. "With the wealth of detailed biological data available in this project, we look forward to a close collaboration with GNS to build a predictive model to elucidate novel insights into this complex disease."

About Multiple Myeloma

Multiple myeloma is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. In multiple myeloma, collections of abnormal plasma cells accumulate in the bone marrow, where they interfere with the production of normal blood cells. Most cases of myeloma also feature the production of a paraproteinan abnormal antibody which can cause kidney problems. Bone lesions and hypercalcemia (high calcium levels) are also often encountered. Myeloma is diagnosed with blood tests (serum protein electrophoresis, serum free kappa/lambda light chain assay), bone marrow examination, urine protein electrophoresis and X-rays of commonly involved bones. Myeloma is generally thought to be treatable but incurable. Remissions may be induced with steroids, chemotherapy, proteasome inhibitors (e.g. bortezomib), immunomodulatory drugs (IMiDs) such as thalidomide or lenalidomide and stem cell transplants. Radiation therapy is sometimes used to reduce pain from bone lesions. Myeloma develops in 1-4 per 100,000 people per year. It is more common in men, and for unknown reasons is twice as common in African-Americans as it is in white Americans. With conventional treatment, median survival is 3-4 years, which may be extended to 5-7 years or longer with advanced treatments. Multiple myeloma is the second most common hematological malignancy in the U.S. (after non-Hodgkin lymphoma) and constitutes 1 percent of all cancers.

About REFS

REFS (Reverse Engineering and Forward Simulation) is GNS Healthcare's scalable, supercomputer-enabled framework for discovering new knowledge directly from data. REFS automates the discovery and extraction of causal network models from observational data and uses high-throughput simulations to generate new knowledge.

Read this article:
GNS Healthcare, Dana-Farber and Mount Sinai Collaborate to Build Computer Model of Multiple Myeloma

Keynote Speaker: Daniel Kraft bull; Presented by SPEAK Inc.
Stanford and Harvard Trained Physician-Scientist, Inventor, Entrepreneur and Innovator Dr. Daniel Kraft has over 20 years of experience in clinical practice, biomedical research and healthcare innovation. Daniel chairs the Medicine track for Singularity University and is Executive Director for FutureMed, a program which explores convergent, exponentially developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees at Brown and medical school at Stanford, Dr. Kraft was board certified in the Harvard combined Internal Medicine and Pediatrics residency program at the Massachusetts General Hospital and Boston Children`s Hospital. He went on to complete Stanford fellowships in hematology/oncology bone marrow transplantation, and extensive research in stem cell biology and regenerative medicine. He has multiple scientific publications (including in Nature and Science), medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at UCSF. Dr. Kraft recently founded IntelliMedicine, focused on enabling connected, data driven, and integrated personalized medicine. He is also the inventor of the MarrowMiner, an FDA approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell based regenerative ...From:speakincViews:0 0ratingsTime:14:53More inPeople Blogs

See the rest here:
Keynote Speaker: Daniel Kraft • Presented by SPEAK Inc. - Video

Timothy J. Triche, MD PhD DBRM Retreat 2012 Genomics and Stem Cell Research
Non Coding RNA Functional RNA Transcripts in Cancer and Development Professor of Pathology, Cancer Biology, Pediatrics Keck School of Medicine of the University of Southern California Director, Center for Personalized Medicine at Children #39;s Hospital Los AngelesFrom:Clarence WigfallViews:6 0ratingsTime:17:49More inScience Technology

Read more:
Timothy J. Triche, MD PhD DBRM Retreat 2012 Genomics and Stem Cell Research - Video

ALBANY, New York, Aug. 23, 2012 /PRNewswire/ -- Twease.org - New Report Added in Pharmaceuticals Reports Database Companion Diagnostics and Personalized Medicine Market Report 2012 [http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm]

This is the latest and most up-to-date Market Report from Select Biosciences addressing the companion diagnostics (CDx) and personalized medicine marketplace. Personalized medicine is a broad field with several stakeholders all of which must be aligned in order to capture the immense potential value in targeting therapeutics to the correct patient populationthe field of stratified medicine.

To Browse Full Toc Visit: http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm [http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm]

Companion Diagnostics has been rapidly expanding over the past 3 years and in this market report we describe the current state of the marketplace from the following perspectives:

Related Reports:

Personalized Medicine Market [http://www.twease.org/report/companion-diagnostics-and-personalized-medicine-market-report-2012.htm]

MicroRNAs and Exosomes Market [http://www.twease.org/report/micrornas-and-exosomes-market-report-2012.htm]

MicroRNA Market [http://www.twease.org/report/microrna-market-trends-2011.htm]

MicroRNA Research and Disease Associations [http://www.twease.org/report/microrna-research-and-disease-associations-2010-market-report.htm]

Circulating Tumor Cells [http://www.twease.org/report/circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-global-industry-size-market-share-trends-analysis-and-forecasts-2012-2018.htm]

Go here to read the rest:
Companion Diagnostics and Personalized Medicine Market Report 2012: Twease.org

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vxwrkb/personalized_medic) has announced the addition of the "Personalized Medicine - A Global Market Overview" report to their offering.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine - Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology.

The report covers the brief business profiles of 56 key global players and 77 major players across the United States - 45; Europe - 24; and Rest of World - 8.

The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

For more information, including table of contents and list of companies mentioned, please visit http://www.researchandmarkets.com/research/vxwrkb/personalized_medic

Read the original:
Research and Markets: Personalized Medicine - A Global Market Overview

NEW YORK, Aug. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0955290/Personalized-Medicine---A-Global-Market-Overview.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

`Personalized Medicine can mean a lot of things to a lot of people. For some, it may relate to doctors having knowledge about their case history and the treatment received, which is a morale boosting factor, since everybody wants caregivers who can comprehend an individual's problems. The day is not very far when this level of personal or individual understanding between a patient and a doctor would be much deeper than hitherto anticipated. The coming decade is expected to witness an increase in the use of companion diagnostics and personalized medicines, with pricing incentives and efficiency improvement propelling the market. Current market leaders with diagnostic divisions focusing on biomarker identification would be at an advantage.

This report review, analyze and projects the personalized medicine market for global and the regional markets including the United States, Europe and Rest of World. The market numbers illustrated in this report only represent the market exclusively for the product segments and technologies enunciated above. The market, in this report, does not include the associated hardware equipment or software technologies that are used to manage patient data. The study includes recent and current trends related to technology and the market along with the key industry developments.

The market for personalized medicine product types analyzed in this study includes Targeted Biologics, Proteomics & Genomics, Genetically Modified (GM) Products, Wellness & Disease Management, Other Molecular Diagnostics and Self/Other Diagnostics. The report also includes the market analysis for application technologies of personalized medicine Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics, Pharmacogenetics and Other Technologies. The report analyses the global market in terms of USD Million.

This 350 page global market report includes 43 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of the market. The statistical tables represent the data for the global market by geographic region, product type and application technology. The report covers the brief business profiles of 56 key global players and 77 major players across the United States 45; Europe 24; and Rest of World 8. The report also provides the listing of the companies engaged in research and development, manufacturing, processing, supplies and distribution of personalized. Also enlisting the academic institutions engages in personalized medicine, the global list covers the addresses, contact numbers and the website addresses of 395 companies.

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION1.1 Product Outline1.1.1 Personalized Medicine's Influence on Large Scale Studies1.1.2 Gazing into the Crystal Ball: What the Future Holds for Personalized Medicine1.1.3 Ramifications of Personalized Medicine for Healthcare Systems1.1.3.1 Pharmaceutical Industry1.1.3.2 Diagnostics Industry1.1.3.3 Insurers1.1.3.4 Physicians1.1.3.5 Government Agencies1.1.3.6 Patients1.1.4 Analysis of Personalized Medicine by Segment1.1.4.1 Targeted Biologics1.1.4.1.1 Overview1.1.4.1.2 Targeted Biologics for Breast Cancer: An Illustration1.1.4.2 Proteomics & Genomics1.1.4.2.1 Proteomics1.1.4.2.1.1 A Complex Problem1.1.4.2.1.2 Post-Translational Modifications1.1.4.2.1.3 Phosphorylation1.1.4.2.1.4 Ubiquitination1.1.4.2.1.5 Other Modifications1.1.4.2.2 Genomics1.1.4.2.2.1 Pharmacogenomics1.1.4.3 Genetically Modified (GM) Products1.1.4.3.1 The Genetic Engineering Process1.1.4.3.1.1 Applications of Genetic Engineering1.1.4.4 Wellness & Disease Management1.1.4.4.1 Wellness Defined1.1.4.4.2 Disease Management Defined1.1.4.5 Molecular Diagnostic Technologies1.1.4.5.1 DNA Sequencing1.1.4.5.2 Biochips and Microarrays1.1.4.5.3 Cytogenetics1.1.4.5.3.1 Personalized Medicine Based on Molecular Cytogenetics1.1.4.5.3.2 Personalized Medicine Based on Cytomics1.1.4.5.4 Single Nucleotide Polymorphism (SNP) Genotyping1.1.4.5.4.1 Applications of SNPs Pertinent to Personalized Medicine1.1.4.5.5 Haplotyping1.1.4.5.6 Application of Proteomics In Molecular Diagnosis1.1.4.5.7 Gene Expression Profiling1.1.4.5.8 Personalized Medicine and Molecular Imaging1.1.4.5.9 Diagnostics Based On Glycomics1.1.4.5.10 Combining Diagnostics and Therapeutics1.1.4.5.11 Point-Of-Care (POC) Diagnosis1.1.4.5.12 Genetic Testing For Disease Predisposition1.1.5 Analysis of Personalized Medicine by Technology1.1.5.1 Pharmacogenomics1.1.5.1.1 Drug Metabolism1.1.5.1.2 Applications1.1.5.2 Point-of-Care Testing1.1.5.2.1 Tests that are Most Apt for Specific Scenarios1.1.5.2.2 Advantages1.1.5.3 Stem Cell Therapy1.1.5.3.1 Treatment with Stem Cells1.1.5.3.2 Current Therapies1.1.5.3.3 Future Treatments1.1.5.4 Pharmacoproteomics1.1.5.5 Pharmacogenetics1.1.5.5.1 Prediction of Drug-Drug Interactions1.1.5.5.2 Integration of Pharmacogenetics with the Healthcare System1.1.5.5.3 Pharmacogenetic Tests1.1.5.6 Other Personalized Medicine Technologies1.1.5.6.1 Biochips1.1.5.6.2 Genetic Screening1.1.5.6.3 Metabolomics1.1.5.6.4 Molecular Diagnostics1.1.5.6.5 Pharmacodynamics1.1.5.6.6 Pharmacokinetics1.1.5.6.7 SNP Genotyping1.1.6 The Rationale Behind Personalized Medicine: "One Size no Longer Fits All"1.1.7 The Human Genome: What is It?

2. KEY MARKET TRENDS

Combating Melanoma and Lung Cancer Facilitated Using Novel Personalized Drugs

Read more:
Personalized Medicine - A Global Market Overview